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Steven Jones, Grac¸a Porto, Marco Marra, Maria De Sousa, and Greg Vatcher
Hereditary hemochromatosis (HH) is clas-
sically associated with a Cys282Tyr
(C282Y) mutation of the HFE gene. Non-
C282Y HH is a heterogeneous group ac-
counting for 15% of HH in Northern Eu-
rope. Pathogenic mutations of the
transferrin receptor 2 (TfR2) gene have
been identified in 4 Italian pedigrees with
the latter syndrome. The goal of this
study was to perform a mutational analy-
sis of the TfR2 and HFE genes in a cohort
of non-C282Y iron overload patients of
mixed ethnic backgrounds. Several se-
quence variants were identified within the
TfR2 gene, including a homozygous mis-
sense change in exon 17, c2069 A3C,
which changes a glutamine to a proline
residue at position 690. This putative mu-
tation was found in a severely affected
Portuguese man and 2 family members
with the same genotype. In summary,
pathologic TfR2 mutations are present
outside of Italy, accounting for a small
proportion of non-C282Y HH. (Blood.
2002;100:1075-1077)
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Introduction
In 1996, Feder et al1 identified 85% of hereditary hemochromatosis
(HH) patients of Northern European descent as being carriers of a
C282Y mutation in the HFE gene. Since 1996, several other
mutations of the HFE gene have been identified in association with
HH2-4; however, with rare exception, these mutations occur in
tandem with trans C282Y mutations and are infrequent causes
of HH.
Mutations of the transferrin receptor 2 (TfR2) gene have been
implicated as the genetic basis of a novel autosomal recessive
adult-onset HH syndrome in 4 Italian pedigrees (Hemochromato-
sis, Type 3, OMIM 604250).5-6 The TfR2 transcript is a homolog
of the transferrin receptor (TfR1) protein with 48% identity and
66% similarity in the extracellular portion of the protein.7 TfR2 has
both similar and distinct functional properties from TfR1, including
a common affinity for diferric transferrin7 and a lack of affinity for
the HFE protein,8 respectively. Nonsense or nonfunctional muta-
tions of TfR2 are associated with HH5-6; however, the frequency
and physiologic basis of this association are unclear.
The goal of the current study was to identify a genetic basis for
iron overload in a cohort of patients with non-C282Y iron overload
by direct sequencing of both the TfR2 and the HFE genes.
Study design
The study population consisted of all patients referred to the Molecular
Diagnostic Laboratory of Children and Women’s Health Centre in Vancou-
ver, BC, Canada, for genetic testing for HH prior to May 5, 2000. From this
database, we selected all patients with a transferrin saturation greater than
or equal to 60%, an elevated serum ferritin level, and a negative test result
for the C282Y HFE mutation. From the same laboratory, 93 control samples
were obtained.
Testing for the HFE C282Y mutation was performed according to
standard methods. Polymerase chain reaction (PCR) amplification and
direct sequencing of all coding regions and all intron/exon boundaries of the
HFE and TfR2 genes were performed on each patient at the British
Columbia Genome Sequencing Centre (BCGSC).
Method details are available in the supplementary information stored on
the BCGSC website (www.bcgsc.bc.ca/fg/hemoc). The project received
approval from the ethical review boards of all participating institutions.
Investigations were undertaken with the informed consent of all study
participants.
Results and discussion
HFE and TfR2 sequencing was performed on DNA from 89
patients of mixed ethnic origin (patient demographic data available
in the supplementary information). Of these patients, 15 had risk
factors for secondary iron overload. Among this cohort, one
probable pathogenic mutation of the TfR2 gene was identified,
c2069 A3C, Q690P (Figure 1). This novel mutation occurred in a
single patient who was a child of a consanguineous marriage
(Figure 2). The remaining patients either did not have a TfR2 or
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HFE genotype suggestive of HH (n 74) or had genotypes
associated with normal or mild iron overload status (HFE H63D/
H63D, n 11; HFE H63D/S65C, n 3).9-11 In addition, 18 TfR2
polymorphisms were identified, including 3 novel and one previ-
ously described12 amino acid coding changes (Figure 1 and
www.bcgsc.bc.ca/fg/hemoc). Five HFE single nucleotide polymor-
phisms were identified (www.bcgsc.bc.ca/fg/hemoc).
With respect to HFE mutations, a high percentage of patients
carried the HFE H63D allele (48 of 89; 54%). This value is above
that expected as compared to carrier rates for H63D ranging from
12% to 37% in European population studies.13 This overrepresenta-
tion of HFE H63D genotypes is in keeping with the hypothesis that
HFE H63D mutations contribute to an iron overload phenotype,
even in the absence of the HFE C282Y allele.14-15
The TfR2 Q690P mutation was identified in an individual of
Portuguese descent. He presented at 29 years of age with fatigue,
hypogonadotropic hypogonadism, hyperpigmentation, mild eleva-
tion of liver transaminases, and idiopathic thrombocytopenic
purpura. He had markedly elevated serum iron indices (Figure 2)
and has had more than 12 g of iron removed via phlebotomy in the
past 4 years. Additional hematologic abnormalities included mild
normocytic anemia and lymphopenia. He is heterozygous for the
HFE H63D mutation. The Q690P mutation was not identified in
our control group, 20 Portuguese controls, and 39 Portuguese
patients with nonclassical HH.
The family of the Q690P proband was investigated for iron
overload and the presence of the TfR2 Q690P mutation. The results
of the family study are summarized in Figure 2 (additional data
available at www.bcgsc.bc.ca/fg/hemoc). Biochemical evidence of
iron overload was detected in 2 female siblings (IV-3 and IV-4 in
Figure 2), both of whom are homozygous for the TfR2 Q690P
mutation. They had no clinical manifestations of disease aside from
arthralgia, which affected sibling IV-3. Sibling IV-3 had a trans-
ferrin saturation level measured at greater than 100% with a normal
serum ferritin and no evidence of hepatic iron overload as assessed
by magnetic resonance imaging.16 Her hematologic profile re-
vealed neutropenia but was otherwise normal. She has a wild-type
HFE genotype. Sibling IV-4 had a transferrin saturation value of
77% and elevations of serum ferritin and hepatic iron stores (263
mol/g). Her hematologic profile revealed a mild normocytic
anemia and lymphopenia. She is heterozygous for the HFE H63D
mutation. Sibling IV-1 and the mother of the proband showed no
evidence of an iron overload phenotype or hematologic abnormali-
ties. The mother is heterozygous for the TfR2 Q690P allele, while
sibling IV-1 is wild type.
The impact of the Q690P mutation on TfR2 function can be
estimated by analysis of the corresponding position in the homolo-
gous TfR1 protein (threonine 658). TfR1 thr658 is residue 18 of 23
amino acids forming the  helix 3 of the helical domain in the
extracellular component of the protein.17 Sixteen of the 23 amino
acids are identical or structurally conserved between TfR1 and
TfR2.17 In TfR1, this  helix forms the proposed binding sites for
both diferric transferrin and HFE.17-18 Specifically, mutagenesis of
TfR1  helix 3 amino acids 643, 646–648, and 650 all yield TfR1
proteins with significantly reduced affinity for transferrin.18-19
Therefore, disruption of the  helix 3 secondary structure via
insertion of a proline residue at position 690 in TfR2 (position 658
in TfR1) would be expected to disrupt a key binding site for diferric
transferrin. This loss of function could then manifest as an iron
overload phenotype similar to that associated with TfR2 non-
sense mutations.
The strong clinical expression of HH in the proband and family
members with the Q690P homozygous mutation suggest that the
TfR2 interaction with transferrin plays a critical role in normal iron
homeostasis. However, because TfR2 is primarily expressed in
hepatocytes and in erythroid precursors,20 much remains to be
elucidated as to how an abnormal interaction with the transferrin
protein results in systemic iron overload.
In our cohort of non-C282Y HH patients of predominately
mixed European descent, only 1 of 89 was found to have a novel
pathogenic mutation of either the TfR2 or HFE genes. The isolated
nature of this finding is concordant with previous studies of
TfR212,21-22 or HFE15,23 in non-C282Y homozygous HH. However,
the identification of the TfR2 Q690P mutation helps to establish
TfR2 mutations as infrequent but important contributors to autoso-
mal recessive adult-onset HH. This patient’s family is the first
TfR2-associated HH pedigree to be described outside Italy.
Figure 1. Summary of new and previously described coding sequence changes
of the TfR2 gene. Text box color code is as follows: purple indicates previously
described homozygous mutations, white indicates a novel homozygous mutation,
and orange indicates heterozygous sequence changes. The asterisk indicates a
previously described heterozygous sequence change. For each sequence change
identified in this study, both the amino acid (above) and cDNA nucleotide (below)
changes are indicated.
Figure 2. Q690P pedigree. Age (A, years), ferritin (F, g/L), transferrin saturation (S,
%), and TfR2 Q690P and HFE H63D mutation status for the Portuguese family.
“” indicates the presence of the mutant allele, and “” indicates its absence. The
mother was heterozygous for both TfR2 Q690P and HFE H63D. Abnormal results
are indicated in bold type. Values listed are those of the initial assessment for
each patient.
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